Results 181 to 190 of about 165,820 (336)

Long‐term patient‐reported outcomes of open urorectal fistula repair after prostate cancer treatment

BJU International, EarlyView.
Objectives To evaluate long‐term outcomes of open urorectal fistula (URF) repair, including URF recurrence, need for re‐intervention, and patient‐reported outcomes. Patients and Methods This retrospective study included men undergoing open URF repair between 2014 and 2024.
Max C. Wagner, Jakob Klemm, Navid Roessler, Robert J. Schulz, Dejan K. Filipas, Margit Fisch, Roland Dahlem, Malte W. Vetterlein   +7 more
wiley   +1 more source

Adult congenital adrenal hyperplasia presenting with severe clitoromegaly and distal vaginal stenosis: A reconstructive surgical case report. [PDF]

Urol Case Rep
Alatawi M, Barry M, Almannie R, Althunayan A, Albassam AA, Aldakhil LO.   +5 more
europepmc   +1 more source

Long‐term outcomes following a 5‐year recurrence‐free interval in non‐muscle‐invasive bladder cancer

BJU International, EarlyView.
Objective To describe the recurrence and progression trends of non‐muscle‐invasive bladder cancer (NMIBC) during a 14‐year period in Denmark between 2009 and 2022. Furthermore, to evaluate the risk of late recurrence with or without progression in patients who initially experience a 5‐year recurrence‐free interval (RFI).
Peter B. Hjort, Jørgen B. Jensen, Andreas Ernst   +2 more
wiley   +1 more source

Unclassified complex urogenital anomaly in a 3-year-old girl: Diagnostic and surgical challenges. [PDF]

Urol Case Rep
Manghi I, Gargano T, Ruspi F, Maffi M, Libri M, Domini M.   +5 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Editorial: Advances in pharmacological treatments for urogenital disorders. [PDF]

Front Urol
Wang X, Wang P, Yu Q.
europepmc   +1 more source

Urogenital [PDF]

Mucosal Immunology, 2009
openaire   +1 more source

Circulating Musclin is associated with skeletal muscle function and subclinical cardiac dysfunction in patients with cancer

British Journal of Pharmacology, EarlyView.
Background and Purpose Musclin (osteocrin) is a skeletal muscle‐derived peptide that has been implicated in cardioprotective signalling pathways. Its relevance in cancer patients, who frequently experience muscle wasting and cardiotoxicity, remains unclear. This study aimed to determine whether circulating Musclin levels reflect functional capacity and
Jannek Brauer, Daniel Finke, Sebastian Romann, Norbert Frey, Joerg Heineke, Lorenz H. Lehmann   +5 more
wiley   +1 more source

A feline case of suspected partial persistent urogenital sinus successfully managed by urethral plication alone. [PDF]

JFMS Open Rep
Ogawana T, Fukui S, Kanemoto H.
europepmc   +1 more source

Outbreak of urogenital schistosomiasis in Corsica (France): an epidemiological case study.

Lancet. Infectious Diseases (Print), 2016
J. Boissier, S. Grech-Angelini, B. Webster, J. Allienne, T. Huyse, S. Mas‐Coma, E. Toulza, H. Barré-Cardi, D. Rollinson, J. Kincaid-Smith, A. Oleaga, R. Galinier, J. Foata, A. Rognon, A. Berry, G. Mouahid, Rémy Henneron, H. Moné, H. Noel, G. Mitta   +19 more
semanticscholar   +1 more source